In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide.

Alex Brenchat, PhD, is VP and practice area lead for local pharmacovigilance services at PharmaLex. Brenchat has more than 20 ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

Novo Nordisk (NYSE: NVO) has sparked investor interest primarily because of its weight loss treatments. Where to invest ...

AIMRC & WECARE will host Juleen Zierath of the Karolinska Institute, Stockholm, at 12:55 p.m. Wednesday, Jan. 15, at the Jones Family Student-Athlete Success Center, room 104.

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

Novo Nordisk (NYSE: NVO) has found phenomenal success in treating patients with obesity and diabetes. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...

Viking Therapeutics ( VKTX 4.30%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...